Four things to know:
- The lawsuit accuses Viatris of using its monopoly on EpiPen auto-injectors to raise the cost excessively.
- The agreement is awaiting the court’s approval. If it is approved, Viatris would admit no wrongdoing.
- EpiPens are manufactured by two Pfizer subsidiaries — King Pharmaceuticals and Meridian Medical Technologies — and sold by Viatris in the U.S. In July, the subsidiaries agreed to pay $345 million to settle EpiPen price hike allegations.
- “The company maintains that it acted lawfully and pro-competitively and the settlement contains no admission of liability,” Viatris said in its quarterly earnings report. “The board of directors believes that this settlement is in the best interests of the company and its stakeholders.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
